News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Capital Clean Energy Carriers reported Q3 revenue $129.14M and EPS $0.57, beating expectations.
  • Management forecasts earnings lift from upcoming vessel deliveries and long-term charters.
  • Shares trade below recent highs despite the reported fundamentals.
  • Market capitalization stands at $1.24B with price-to-book below 1 and P/E near 10.
  • Analysts outline an actionable mid-term long trade with defined entry, stop, and target.
  • Trade proposal emphasizes a balanced risk framework for investors.

Latest Articles

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Ligand Pharmaceuticals has entered a financing agreement with AvenCell Therapeutics to provide up to $47 million to support clinical development of AvenCell's allogeneic CAR-T therapies targeting acute myeloid leukemia and B-cell malignancies. Ligand will receive royalties on the sales of AvenCell's pipeline assets, with funding released upon achie…

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen announced positive exploratory findings from two clinical trials indicating that its lead product candidate, fasedienol nasal spray, shows potential efficacy in treating individuals with very severe social anxiety disorder. These findings include statistically significant improvements in anxiety symptoms during public speaking challenges a…

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Satellos Bioscience Inc. announced FDA clearance of its IND application to begin a Phase 2 clinical trial for forazapadin, a novel oral small molecule drug candidate aimed at muscle regeneration, targeting facioscapulohumeral muscular dystrophy (FSHD). The company secured up to $5 million in non-dilutive financing from the FSHD Canada Foundation to…

AMD: Memory-Heavy AI Agents Turn a Competitive Edge into a New TAM

AMD: Memory-Heavy AI Agents Turn a Competitive Edge into a New TAM

Advanced Micro Devices (AMD) is uniquely positioned to benefit as AI adoption shifts from monolithic models to memory-hungry agents and context-rich workloads. With data-center revenue doubling year-over-year and a market cap north of $1 trillion, AMD trades at a premium but has measurable product and demand catalysts that justify a tactical long i…

Descartes Expands AI Innovation with Agent that Helps Reduce Global Trade Data Research and Analysis Time by Up to 90%

Descartes Expands AI Innovation with Agent that Helps Reduce Global Trade Data Research and Analysis Time by Up to 90%

Descartes Systems Group launched the Descartes Datamyne AI Agent, a cutting-edge conversational AI integrated into its global trade intelligence platform. The AI Agent leverages over 500 million annual shipment records from 230 markets to help logistics, sourcing, sales, and supply chain teams reduce trade data research and analysis time by up to 9…

Ducommun’s CEO Sets the Stage for Continued Success, Unveiling the VISION 2032 Game Plan at Investor Day

Ducommun’s CEO Sets the Stage for Continued Success, Unveiling the VISION 2032 Game Plan at Investor Day

Ducommun Incorporated held its first Investor Day in four years, reporting strong progress against its VISION 2027 strategic plan and unveiling the VISION 2032 roadmap. The company aims to accelerate growth through expanded acquisitions, defense franchise expansion, commercial aerospace recovery, and investment in proprietary engineered products. I…

Comstock And Sierra Springs Opportunity Fund Announce Strategic Engagement With Newmark For Its Nevada Land-Power-Compute Platform

Comstock And Sierra Springs Opportunity Fund Announce Strategic Engagement With Newmark For Its Nevada Land-Power-Compute Platform

Comstock Inc. and its strategic investment Sierra Springs Opportunity Fund have engaged Newmark, a leading commercial real estate advisory firm, to develop and optimize their significant powered land position in Silver Springs, Nevada. The engagement aims to strategically position the 2,200-acre land portfolio, including infrastructure and faciliti…

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova announced the completion of the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS clinical trial evaluating MN-166 (ibudilast) for ALS treatment. The trial involved 234 participants in the US and Canada. The company expects topline data by end of 2026 and continues with an open-label extension phase. MN-16…

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix, Inc. announced progress in two complementary Molecular Residual Disease (MRD) monitoring programs—tumor-informed and tumor-naïve approaches—to detect circulating tumor DNA for cancer monitoring post-treatment. The tumor-informed method leverages a collaboration with Bio-Rad using Droplet Digital PCR technology, and the tumor-naïve method …

TJGC Group Limited Announces Share Repurchase Program

TJGC Group Limited Announces Share Repurchase Program

TJGC Group Limited announced a Board-approved share repurchase program authorizing up to $2 million of its Class A ordinary shares. The program reflects management's confidence in the company's long-term growth and commitment to disciplined capital allocation. Repurchases may occur via open market, block trades, or private transactions, funded from…

KBR Welcomes Chief Executive Officer of Trinzic, the Spin-off of its Mission Technology Solutions Business, and Announces New Investor Relations Lead

KBR Welcomes Chief Executive Officer of Trinzic, the Spin-off of its Mission Technology Solutions Business, and Announces New Investor Relations Lead

KBR has appointed Michael LaRouche as President and CEO-Designate of Trinzic, the forthcoming independent public company resulting from the spin-off of KBR's Mission Technology Solutions business, planned for January 4, 2027. Trinzic will focus on national security and space mission technologies with over $5 billion in revenue and 18,000 employees …

Fervo Energy Achieves First Power at Cape Station, a Landmark Moment for the Future of Enhanced Geothermal Systems

Fervo Energy Achieves First Power at Cape Station, a Landmark Moment for the Future of Enhanced Geothermal Systems

Fervo Energy has reached a historic milestone by achieving First Power at Cape Station, its flagship Enhanced Geothermal System (EGS) project in Utah. This marks the first utility-scale greenfield EGS project to synchronize to the grid and export electricity, validating EGS as a scalable source of reliable, 24/7 carbon-free power. The 100 MW Phase …

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Kyverna Therapeutics announced positive one-year topline data from its registrational Phase 2 trial KYSA-8 for miv-cel (KYV-101) in stiff person syndrome (SPS) and longer-term Phase 2 follow-up data from KYSA-6 in generalized myasthenia gravis (gMG). The data demonstrate sustained clinical improvements, reversal of disability, and a well-tolerated …

Buy BW LPG Now - A 10-12 Month Trade Ahead of Newbuild Slowdown

Buy BW LPG Now - A 10-12 Month Trade Ahead of Newbuild Slowdown

BW LPG is a cyclical shipping name with a modern VLGC fleet and exposure to strengthening LPG flows. We initiate a 10-12 month buy trade based on an expected lag between recovering earnings and newbuild deliveries, a favorable age profile of the fleet, and multiple catalysts that should re-rate the stock. Entry $6.50, target $9.50, stop loss $4.50.

Jacobs: AI-Driven Backlog and Margin Leverage Make a Convincing Long Trade

Jacobs: AI-Driven Backlog and Margin Leverage Make a Convincing Long Trade

Jacobs Solutions has leaned into higher-margin advisory and AI-related infrastructure work, translating into raised guidance and meaningful backlog growth. At a market cap near $16.5B and free cash flow of roughly $645M, the case for a long trade is operationally grounded. This is a tactical long with a clear entry, stop and $170 target over a 180 …

Fortuna CEO to present at Mining Forum Americas 2026

Fortuna CEO to present at Mining Forum Americas 2026

Fortuna Mining Corp. announced that CEO Jorge A. Ganoza will present at the upcoming Mining Forum Americas 2026, a major event focusing on precious metals equities. The company highlighted its ongoing projects and future production targets, including reaching an annualized production rate of approximately 500,000 gold equivalent ounces by the secon…